Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock shows a 1 day return of about a 1% decline, a 4.4% gain over the past week ...

The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new ...

Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple Sclerosis ...

The sale reduced Biogen to 0.03% of reported U.S. equity assets under management as of September 30. Top holdings after the filing: NASDAQ:MSFT: $164.85 million (13.9% of AUM) NASDAQ:AAPL: $122.68 ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Shares of Biogen Inc. BIIB slipped 3.95% to $178.30 Tuesday, on what proved to be an all-around grim trading session for the ...

Florida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter. After the transaction, J. L. Bainbridge reported holding just 2,969 shares of Biogen ...